Cubist Pharmaceuticals, Inc. Reports First $100 Million Revenue Quarter; Q2 2008 Total Revenues $101.8 Million; Total Net Product Revenues $101.4 Million

LEXINGTON, Mass.--(BUSINESS WIRE)--Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today reported its first $100 million revenue quarter. For the second quarter ended June 30, 2008, Cubist’s net revenues from CUBICIN® (daptomycin for injection) increased 46% from the prior year, from $69.5 million in the second quarter of 2007 to $101.4 million in the second quarter of 2008. Total revenues for the second quarter of 2008 increased 46% over the second quarter of 2007 from $69.8 million in the second quarter of 2007 to $101.8 million in the second quarter of 2008.